StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Keytruda (pembrolizumab by Quarter

Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Keytruda (pembrolizumab: -1.0% in Q2 2026, down 10.0 pts from a year earlier. That is the lowest of the 33 quarters on record here.

Latest, Q2 2026
-1.0%
Period ended Jun 30, 2026
Change on a year earlier
-10.0 pts
9.0% in Q2 2025
History
33 quarters
Since Q4 2017
Sources
33
Documents cited below

Where the Q2 2026 figure comes from

“|| Keytruda | 7,904 | 7,956 | -1 | 4,611 | 4,749 | -3 | 3,293 | 3,207 | 3”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKeytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-1.0%-10.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20256.0%-13.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202510.0%-7.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 20259.0%-7.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 20254.0%-16.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202419.0%-2.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202417.0%0.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202416.0%-3.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202420.0%0.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202321.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202317.0%-3.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202319.0%-7.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202320.0%-3.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 202220.0%-2.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202226.0%+3.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202223.0%+4.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Cite this data

StockData. (2026). Merck Keytruda (pembrolizumab (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-keytruda-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.